New AYUSH medicines in the pipeline to treat diabetes

The diabetic population in the country is close to hitting the alarming mark of 69.9 million by 2025, which denotes that the country is expected to witness an increase of 266%, according to the Union Ministry of AYUSH which has launched many steps to treat diabetes through Indian medicines.

Council of Scientific and Industrial Research (CSIR) has helped development of a few medicines. One CSIR-National Botanical Research Institute (CSIR-NBRI), Lucknow developed scientifically validated herbal product as anti-diabetic formulation and the knowhow for the product was licensed to AIMIL Pharma Ltd., Delhi who are manufacturing and marketing it as BGR-34, across the country. The company has carried out the clinical study and the formulation has shown therapeutic efficacy for treating newly diagnosed type 2 diabetes.

The Central of Research in Ayurveda Sciences (CCRAS) had developed the AYUSH82 formulation for diabetes through scientific process of drug development and commercialized through National Research Development Corporation (NRDC) for wider public utility.

CCRAS has done efficacy and safety on formulations viz. Nishamalki churna, Saptvinsti Gugullu, Yasad bhasm, Guduchi churna, Chandraprabha vati, Haridra churna anmd Gokshuradi Gugullu.


Please enter your comment!
Please enter your name here